In an effort to speed up progress on its genetic testing portfolio and its planned therapeutic work, Interleukin Genetics Inc. acquired consumer products firm Alan James Group LLC and secured $30 million in financing. (BioWorld Today) Read More
The letter from a major shareholder of Nabi Pharmaceuticals Inc., attacking CEO Thomas McLain for the company's "abysmal" performance and "bargain-basement stock price," sent Nabi's shares up about 5 percent on the day it was made public last week, but the story may not be over. (BioWorld Today) Read More
